Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: J Acquir Immune Defic Syndr. 2014 Nov 1;67(3):246–253. doi: 10.1097/QAI.0000000000000312

Figure 3.

Figure 3

Drug resistance mutations detected by OLA, pyrosequencing and consensus sequencing at baseline, and by OLA and consensus sequencing at virologic failure.

Note: Pre-ART specimens were tested by OLA (O), pyrosequencing (P), and consensus sequencing (CS); virologic failure (VF) specimens were tested by OLA and CS only. Numbers indicate the % mutant virus quantified by OLA (bold font, limit of detection = 2%) or pyrosequencing (regular font, limit of detection 0.1%). Dark grey indicates mutation detected by all methods evaluated. Light grey indicates mutation not detected by consensus sequencing, except as indicated for subject #264. Numbers with no shading indicate mutations detected by pyrosequencing only. NT = not tested (due to undetectable HIV viral load). ind = indeterminate result by OLA due to the presence of different mutation. ^ = mutation detected by OLA and consensus sequencing but not by pyrosequencing due to sequence polymorphisms in the region of the pyrosequencing PCR primers.